WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
World game at war: why some European nations have threatened a World Cup boycott 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
MELBOURNE, Australia, April 12, 2018 -- Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP), is pleased to announce that it has been invited to present at the prestigious 6th Annual Cell and Gene Therapy Investor Day in New York.
The conference will take place on the 17th of April 2018 and is organised by the Alliance for Regenerative Medicine (ARM), the leading global industry body for regenerative and advanced therapies.
Around 350 delegates are expected to attend the conference, of which approximately 200 are active investors or analysts. A number of discussion panels will also be held that will see participation from leading analysts and executives from major pharmaceutical companies.
Dr Ross Macdonald, Managing Director and CEO, will present and take part in a fire-side discussion with leading industry analyst, Dr Reni Benjamin of Raymond James, to showcase the Company’s regenerative medicine platform, Cymerus™, and to discuss the positive progress in Cynata’s Phase I clinical trial.
Participation in the highly sought-after event follows the excellent clinical trial data from the analysis of the first patient cohort in the Phase I clinical trial (announced on 22nd January 2018) and the recent granting of Orphan Drug Designation in the US by the FDA (announced 28th March 2018).
To find out more about the event, please go to: https://alliancerm.org/event/cginvestorday. The event is expected to be live streamed and will be available to watch at http://arminvestorday.com/webcast/.
| CONTACTS: | Dr Ross Macdonald, CEO, 0412 119343, [email protected] | |||
| Daniel Paproth, Australia Media Contact, 0421 858 982, [email protected] | ||||
| Laura Bagby, U.S. Media Contact, 312-448-8098, [email protected] | ||||
About Cynata Therapeutics (ASX:CYP)
Cynata Therapeutics Limited (ASX:CYP) is an Australian clinical-stage stem cell and regenerative medicine company developing therapies based on its proprietary Cymerus™ stem cell technology platform. Cymerus overcomes critical issues in the production of therapeutic mesenchymal stem cells (MSCs) by enabling the economical manufacture of commercial-scale MSCs, independent of multi-donor limitations. Cymerus’ novel approach utilises induced pluripotent stem cells (iPSCs) derived from a single blood donation to generate mesenchymoangioblasts (MCAs), a precursor that is used to manufacture an unlimited number of therapeutic MSCs. Cynata’s unique “off-the-shelf” Cymerus platform has the potential to create a new standard in the development and manufacture of stem cell therapeutics.
